Tag Archives: Entheon Biomedical Corp.

Vancouver, British Columbia–(Newsfile Corp. – September 11, 2026) – Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (“Entheon” or the “Company“) announces that it has elected to participate in the Coordinated Blanket Order 51-933 – Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the “Blanket Order“), issued by …

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2026) – Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (“Entheon” or the “Company“) wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company’s news release dated June 9, …

Toronto, Ontario–(Newsfile Corp. – May 25, 2026) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (“Entheon” or the “Company“) announces that further to its news release dated January 19, 2026, the definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026 (the “Business Combination …